Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Niosomal Delivery of Isoniazid - Development and Characterization

Gyanendra Singh¹, Harinath Dwivedi¹, Shailendra K Saraf², Shubhini A Saraf¹

¹Department of Pharmaceutics, Faculty of Pharmacy, Babu Banarasi Das National Institute of Technology & Managemen; ²Faculty of Pharmacy, Northern India Engineering College, Lucknow (Uttar Pradesh), India.

For correspondence:- Shubhini Saraf Email: shubhini.saraf@gmail.com Tel:+915223911132

Received: 10 September 2010 Accepted: 7 February 2011 Published: 20 April 2011

Citation: Singh G, Dwivedi H, Saraf SK, Saraf SA. Niosomal Delivery of Isoniazid - Development and Characterization. Trop J Pharm Res 2011; 10(2):203-210 doi: 10.4314/tjpr.v10i2.12

© 2011 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop a niosomal formulation for the delivery of isoniazid to achieve effective treatment of tuberculosis.

Methods: Niosomes were prepared by reverse phase evaporation method and given a charge with a charge-inducing agent, dicetyl phosphate. Drug entrapment efficiency in the niosomes was determined spectrophotometrically. The niosomes were further characterized for their particle size, polydispersity index (PI) and zeta potential as well as by scanning electron microscopy and stability studies. Furthermore, in vitro drug release and cellular uptake studies on the niosomes by macrophage J744 A were undertaken.

Results: Suitable isoniazid niosomes were obtained. The niosomes demonstrated a potential to remain in the treated site for prolonged periods and were also capable of maintaining steady drug concentrations for up to 30 h. Cellular uptake of the drug-loaded niosomes by macrophage cells was as high as 61.8 %, a level that is capable of achieving effective treatment of tuberculosis.

Conclusion: The isoniazid niosomes developed are capable of reducing drug dose and toxicity as well as dosing frequency which should bring about improved patient compliance. More importantly, macrophage targeting should be feasible at sites where tuberculosis bacteria are harbored.

Keywords: Niosome, Macrophage targeting, Isoniazid, Tuberculosis, Drug release, Cellular uptake